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eDITORIAL COMMENT
he Yin and Yang
f Arterial Inflammation*
oger Mills, MD, FACC,
eepak L. Bhatt, MD, FACC
leveland, Ohio
he recent wave of enthusiasm for including inflammation
s one of the primary pathophysiologic processes in cardio-
ascular disease has substantial merit (1). Arterial inflam-
ation is central to plaque progression and plaque rupture.
mong clinical markers of inflammation, C-reactive protein
CRP), a complex pentameric protein largely of hepatic
rigin, is the current gold standard (2,3). In a variety of
linical situations, the elevation of CRP predicts adverse
utcomes, including mortality (4,5). Beyond its “biomarker”
ole, CRP probably actively participates in atherothrombo-
is. For example, CRP opsonization of low-density lipoprotein
LDL) cholesterol mediates LDL uptake by macrophages.
See page 44
Although CRP has caught our attention, many other
ro-inflammatory factors also indicate patient risk and
articipate in the atherosclerotic process, including interleu-
in (IL)-6, tumor necrosis factor (TNF)-alpha, interferon
amma, monocyte chemoattractant protein-1, cell adhesion
olecules, nuclear factor kappa B, CD 40, lipoprotein-
ssociated phospholipase A2, myeloperoxidase, nitroty-
osine, and matrix metalloproteinase-9 (6). The list of
ffenders grows larger almost weekly.
Although inflammation plays an important part in the
athogenesis of atherothrombotic syndromes, not all in-
ammatory mediators are evil. Analogous to the thrombotic
ascade, inflammatory pathways have counterbalancing fac-
ors to keep the system in check. The inflammatory cascade
aintains a delicate balance of pro- and anti-inflammatory
olecules that regulate homeostatic functioning. Control of
eart rate with a balance of sympathetic and parasympa-
hetic tone and regulation of intravascular volume by a
alance of salt-retaining and -wasting mechanisms provide
ther examples of a basic biological principal: physiological
egulation involves a balance of stimulating and repressing
orces. Our concepts of arterial inflammation should now
xpand to both sides of the equation. Although the focus of
his editorial comment is coronary atherosclerosis, the same
atterns of pro- and anti-inflammatory cytokine balance
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Department of Cardiovascular Medicine, Cleveland Clinic Foundation,Bleveland, Ohio.ccur in congestive heart failure, peripheral arterial disease,
nd stroke (7).
Genetic determinants affect levels of high-sensitivity
RP as well as other inflammatory moieties (8). Beyond
enetics, environmental factors may influence CRP levels as
ell as levels of other inflammatory markers and mediators
9). Obesity, in particular abdominal adiposity, is a powerful
odulator of CRP levels. Adipocytes produce IL-6 in
bundance and lead to CRP production by the liver;
ubcutaneous fat contains messenger ribonucleic acid
mRNA) for CRP as well (10). Exercise and weight loss
esult in lower CRP levels (11). Smoking and hormone
eplacement therapy raise CRP levels, whereas light-to-
oderate alcohol intake is associated with lower CRP levels.
otentially, in patients with periodontitis, antimicrobial
eriodontal treatment may lower levels of inflammatory
arkers, including CRP. Statins, niacin, peroxisome
roliferator-activated receptor gamma and alpha agonists,
nd antiplatelet therapy are just some of the medications
hat have been shown to lower CRP and diminish its
ro-inflammatory effects (12). In the “big picture,” factors
hat lower CRP are generally associated with cardiovascular
enefit and factors that raise CRP are largely detrimental.
long with other potential inflammatory mediators, the
nterplay of these pro- and anti-inflammatory factors may
etermine the state of vascular health (Fig. 1).
In this issue of the Journal, Fichtlscherer et al. (13) have
rovided evidence to link pro- and anti-inflammatory mod-
lators directly to endothelial function. Using plethysmog-
aphy to assess forearm blood flow in patients with coronary
rtery disease, they demonstrated an association between
mpaired endothelial function and elevated CRP. In addi-
ion, their data suggest that higher IL-10 levels preserved
ndothelial vasodilation in response to acetylcholine, even in
he setting of elevated CRP levels. These findings build
pon a substantial body of prior work suggesting that
levated IL-10 levels are beneficial in patients with acute
oronary syndromes, particularly in those with elevated
RP levels (6,14,15).
Interleukin-1, IL-6, IL-12, and IL-18 are all pro-inflam-
atory cytokines, whereas IL-10 is an anti-inflammatory
ytokine (16). Interleukin-10 has several anti-inflammatory
roperties, including the ability to inhibit production of
NF-alpha, IL-8, tissue factor, and matrix metallo-
roteinase-9 (17). Low levels of IL-10 are associated with the
etabolic syndrome in obese women, although obesity itself
s associated with elevation in CRP, IL-6, and also IL-10.
urthermore, various interactions between interleukins and
RP may occur. For example, human coronary artery smooth
uscle cells are capable of producing CRP and can be
timulated to do so by IL-1-beta, IL-6, and TNF-alpha.
articularly relevant to the study by Fichtlscherer et al. (13),
uman recombinant CRP induces expression of IL-18 by
ndothelial cells, an effect inhibited by treatment with IL-10.
lood pressure, in part a reflection of the state of the endo-
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July 7, 2004:50–2 Editorial Commenthelium, may also modulate the production of inflammatory
olecules and vice versa. Inflammatory mediators may con-
ribute to blood pressure elevation, but blood pressure elevation
lso leads to production of cytokines and cell adhesion mole-
ules. In fact, CRP, at clinically relevant concentrations, has
een found to potentiate the effects of angiotensin II by
p-regulating the expression of angiotensin receptors on vas-
ular smooth muscles. C-reactive protein also has been shown
o reduce endothelial nitric oxide (NO) synthase expression
nd prostacyclin release in cultured human cells. In particular,
RP inhibits basal and stimulated NO release by endothelial
ells, apparently through a posttranscriptional effect on endo-
helial NO mRNA stability. The incubation of human saphe-
ous vein endothelial cells with CRP decreased endothelial
elease of NO and increased endothelin-1 production. Because
O and prostacyclin are both potent vasodilators and
ndothelin-1 is a powerful vasoconstrictor, their modulation by
RP could alter vascular tone. Furthermore, CRP, at least in
he setting of acute coronary syndromes, has been shown to
ensitize endothelial cells to destruction by cytotoxic CD4 T
ells. In addition to these effects on the endothelium, CRP
irects the recruitment of monocytes into the intima. In
ummary, the connection between inflammation and endothe-
ial dysfunction suggested by Fichtlscherer et al. (18) has a
ogent biological basis.
In the study by Fichtlscherer et al. (13), a large percent-
ge of patients were receiving aspirin, beta-blockers,
ngiotensin-converting enzyme inhibitors, and statins.
hether the relationship they described between CRP and
igure 1. The balance of pro- and anti-inflammatory mediators may
etermine vascular health or illness. The list of inflammatory molecules, in
articular those that are pro-inflammatory, are rapidly expanding. Some of
he more prominent ones are listed. ACE-I  angiotensin-converting
nzyme inhibitor; ARB angiotensin receptor blocker; CRP C-reactive
rotein; IL  interleukin; MCP  monocyte chemoattractant protein;
MP  matrix metalloproteinase; NF  nuclear factor; PPAR 
eroxisome proliferator-activated receptor; TNF  tumor necrosis factor.L-10 would be greater or lesser in a population not aeceiving such therapy is unknown. Aspirin pretreatment
lunts the effects of inflammation on endothelial dysfunc-
ion, and statin therapy may reverse endothelial dysfunction
hrough both lipid-lowering and anti-inflammatory path-
ays. Good medical therapy in general has been shown to
ower CRP with a corresponding improvement in endothe-
ial function as measured by brachial flow-mediated dila-
ion.
Endothelial dysfunction is not irreversible; therapies that
ower CRP and presumably decrease vascular inflammation
ave already been demonstrated to restore endothelial
ealth. Nevertheless, even with current state of the art
edical therapy, there are still patients who display an
ngoing elevation of inflammatory markers and all that is
mplied by such markers, including endothelial dysfunction.
The work by Fichtlscherer et al. (13) adds further support
o a strategy of multi-marker testing. On a population level,
igh-sensitivity CRP (or any surrogate or pathogenic
arker) is useful, but for any given individual the incremen-
al risk conferred by CRP elevation is relatively modest. The
ichtlscherer et al. (13) findings may help to explain why
ome patients with elevated CRP do not experience adverse
linical events; perhaps these individuals have elevated
L-10 or other counterbalancing factors. Adiponectin, a
ytokine produced by adipose tissue, may be another
ounter-regulatory moiety; adiponectin levels tend to move
n a direction opposite to CRP (10). Low levels of adiponec-
in also correlate with higher levels of IL-6 and phospho-
ipase A2. In the future, point-of-care testing of a panel of
nflammatory markers may help to stratify risk more pre-
isely in both inpatient and outpatient settings. However,
ubstantial further investigation will be required to sort out
he patterns of inflammatory marker expression that have
rue predictive value. Parallel developments in single nucle-
tide polymorphism and haplotype analysis are likely to
omplement these advances. Sophisticated noninvasive im-
ging, such as high-resolution magnetic resonance imaging,
ill probably further refine our ability to detect risk and
llow correlation between abnormal levels of markers and
rterial pathology. Already, higher levels of soluble CD40
igand have been correlated with intra-plaque lipid accumu-
ation in carotid atheroma as assessed by high-resolution
agnetic resonance imaging (19). Future studies will un-
over additional associations between inflammatory marker
evels and in vivo plaque characterization.
Although current efforts have been directed at suppress-
ng inflammation and lowering CRP in particular, raising
L-10 might provide logical complementary or perhaps
ven superior therapy (1), although unopposed anti-
nflammatory activity, such as the blockade of TNF-alpha,
as not proven beneficial in patients with heart disease (20).
erhaps Mother Nature has outwitted us once again, with
ounter-regulatory factors that negate any benefit of oppos-
ng just one particular cytokine. Similarly, human recombi-
ant IL-10 has not been particularly effective in rheumatoid
rthritis and has even been shown to produce some pro-
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Editorial Comment July 7, 2004:50–2nflammatory effects resulting from the up-regulation of Fc
amma receptor expression on macrophages (21). Our
nitial simplistic attempts to alter just one particular element
f the inflammatory cascade are unlikely to have the desired
ffect. As our understanding of the regulation of physiologic
rocesses deepens, the beauty and complexity of counter-
egulatory pathways recalls the ancient Chinese concept of
he natural balance of Yin and Yang, light and dark, positive
nd negative, male and female. Ultimately, only a better
nderstanding of the Yin and Yang of arterial inflammation
ill enhance our ability to prognosticate risk and effectively
esign therapy directed to an individual’s specific risk
rofile.
eprint requests and correspondence: Dr. Roger Mills, Cleve-
and Clinic Foundation, Department of Cardiovascular Medicine,
500 Euclid Avenue, Desk F15, Cleveland, Ohio 44195. E-mail:
illsr@ccf.org.
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